Eisenmenger Syndrome

• Chronic Shunt-Related Pulmonary Vascular Injury: Sustained left-to-right shunting creates chronic elevation of pulmonary blood flow and pressure. This leads to endothelial dysfunction with increased shear stress, activation of inflammatory pathways, and release of vasoactive mediators including serotonin, endothelin-1, and tissue factor. Endothelial cells express increased levels of adhesion molecules, promoting leukocyte infiltration and inflammatory remodeling of the pulmonary vasculature.

• Progressive Pulmonary Vascular Remodeling: The sustained hemodynamic burden triggers structural changes in the pulmonary circulation characterized by medial hypertrophy of arterioles, intimal proliferation, and fibrosis. Smooth muscle cells undergo phenotypic switching to a proliferative, migratory phenotype through downregulation of contractile proteins and upregulation of growth-promoting transcription factors. Pulmonary arteries develop irreversible obliterative changes with plexiform lesions (characteristic pathologic hallmark), thrombotic material deposition, and loss of normal vascular compliance.

• Reversal of Shunt Direction and Right-to-Left Shunting: As pulmonary vascular resistance rises progressively and eventually exceeds systemic vascular resistance, the pressure gradient reverses. Deoxygenated systemic venous blood bypasses the lungs by shunting directly into the systemic circulation through the cardiac defect, resulting in cyanosis, hypoxemia, and secondary erythrocytosis. The right ventricle becomes progressively hypertrophied and dilated from chronic pressure overload, ultimately leading to right heart failure.

• Neurohormonal Activation and Systemic Compensation: Chronic hypoxemia activates compensatory mechanisms including increased erythropoietin production (leading to polycythemia), activation of the sympathetic nervous system, and upregulation of vasoconstrictive pathways. However, these mechanisms ultimately prove maladaptive, causing increased blood viscosity, enhanced thrombotic risk, and further pulmonary vasoconstriction through hypoxic pulmonary vasoconstriction.

• Secundum Atrial Septal Defect (Most Common): Accounts for approximately 35-40% of Eisenmenger syndrome cases; typically develops later in adulthood (4th-5th decade) due to lower initial shunt magnitude and slower vascular remodeling compared to other lesions.

• Ventricular Septal Defect (VSD - Second Most Common): Represents 25-30% of cases; medium to large VSDs produce greater hemodynamic burden and typically progress to Eisenmenger by 2nd-3rd decade; small restrictive VSDs rarely progress due to protective effect of the defect's resistance.

• Patent Ductus Arteriosus (PDA): Accounts for 5-10% of cases; chronic aortic-to-pulmonary shunting creates substantial pulmonary blood flow increase.

• Complete Atrioventricular Septal Defect (Endocardial Cushion Defect): 5-10% of cases; combined atrial and ventricular shunting produces significant pulmonary vascular burden.

• Other Lesions (Less Common): Aortopulmonary window, truncus arteriosus, total anomalous pulmonary venous return, and complex cyanotic lesions (transposition of great arteries with VSD, tetralogy of Fallot with ASD).

• Risk Factors for Accelerated Progression: Younger age at defect onset, larger defect size, higher baseline pulmonary blood flow/pressure, female sex (pregnancy-related progression), smoking, high altitude residence, and genetic predisposition to pulmonary hypertension.

• Cyanosis and Hypoxemia: Central cyanosis evident at rest, typically moderate (SaO₂ 75-85%), worsening with exertion or Valsalva maneuver; patients demonstrate "squatting" behavior (bending at knees and hips) which increases systemic vascular resistance and reduces right-to-left shunt fraction, temporarily improving oxygenation.

• Dyspnea on Exertion (DOE): Progressive limitation of exercise tolerance due to inability to increase cardiac output in setting of fixed pulmonary vascular obstruction; represents cardinal functional complaint and primary activity limitation.

• Syncope and Presyncope: Occurs with exertion or sudden positional changes due to inability to increase pulmonary blood flow with increased systemic venous return; represents high-risk feature associated with sudden cardiac death risk.

• Chest Pain: Atypical or anginal in character; may represent right ventricular ischemia, pulmonary infarction, or thromboembolism.

• Palpitations and Arrhythmias: Atrial fibrillation common; right ventricular ectopy prevalent; tachycardia poorly tolerated due to fixed cardiac output.

• Hemoptysis: Develops in 5-10% of patients; usually mild but can be massive; results from pulmonary infarction, ruptured bronchial vessels, or plexiform lesion rupture.

• Physical Examination - Cyanotic Features:
• Central cyanosis of lips, tongue, oral mucosa, and nail beds
• Clubbing of digits (clubbed fingers and toes) with loss of nail angle—develops in majority of long-standing cases
• Polycythemic plethora with dusky, ruddy complexion
• Telangiectasia on mucous membranes and skin

• Physical Examination - Cardiovascular Findings:
• Single loud S₂ with prominent P₂ (palpable pulmonary component)
• Right ventricular heave/lift at left sternal border (RV hypertrophy)
• Prominent systolic or continuous murmur location depends on underlying defect (holosystolic at left lower sternal border for VSD, systolic at left infraclavicular for PDA)
• Diastolic murmur of pulmonary regurgitation (Graham Steell murmur) from pulmonary hypertension
• Elevated jugular venous pressure (JVP) with prominent v waves indicating tricuspid regurgitation
• Hepatomegaly from hepatic congestion
• Right-sided S₃ or S₄ gallop from RV dysfunction

• Associated Symptoms: Abdominal discomfort from splenic infarction, fatigue, reduced exercise tolerance, progressive dyspnea at rest in advanced stages.

• Electrocardiography (ECG):
• Right axis deviation (QRS axis > +90°)
• Right atrial enlargement (peaked P waves in II, III, aVF—P pulmonale)
• Right ventricular hypertrophy with R wave dominance in V1-V2
• Right ventricular strain pattern with T wave inversions V1-V3
• May show atrial fibrillation or other arrhythmias

• Chest X-Ray Findings:
• Prominent central pulmonary arteries with rapid peripheral pulmonary artery tapering (classic "pruning" appearance)
• Cardiomegaly with right heart predominance
• Right atrial and right ventricular enlargement
• Prominent pulmonary arteries at hila contrasting with peripheral oligemia
• Normal or decreased pulmonary vascular markings peripherally
• May show evidence of previous cardiac surgery or shunting hardware

• Transthoracic Echocardiography (Cornerstone of Diagnosis):
• Visualization of the structural defect (ASD, VSD, PDA, or other shunt lesion)
• Right-to-left shunt demonstration using bubble study (agitated saline contrast) with opacification of left heart chambers after right heart opacification
• Severely dilated right atrium and right ventricle with depressed RV function
• D-shaped interventricular septum indicating RV pressure overload
• Pulmonary artery dilatation (often >40-45 mm)
• Elevated tricuspid regurgitation (TR) velocity allowing non-invasive estimation of RV-to-RA gradient
• Decreased left ventricular size from reduced pulmonary venous return
• Flattened or reversed septal motion from RV pressure predominance

• Cardiac Catheterization (Gold Standard for Hemodynamics):
• Pulmonary vascular resistance (PVR) typically elevated to 8-15+ Wood units (severely elevated, often >5 Wood units defines Eisenmenger)
• Pulmonary artery systolic/diastolic/mean pressures approaching or exceeding systemic pressures
• Right ventricular systolic pressure equal to or exceeding systemic systolic pressure
• Right atrial pressure elevation (5-10 mmHg or higher) reflecting RV dysfunction
• Oximetry step-up or equalization of oxygen saturations between right and left heart chambers (confirming right-to-left shunt)
• Pulmonary capillary wedge pressure typically normal (distinguishing from post-capillary pulmonary hypertension)
• Calculation of Qp:Qs ratio (pulmonary to systemic flow) typically <1.0 due to reversed shunt
• Vasoreactivity testing (acute response to inhaled nitric oxide or other vasodilators) to assess potential for hemodynamic improvement

• Laboratory Studies:
• Complete blood count: Polycythemia with hemoglobin 15-20+ g/dL and hematocrit 45-60%+
• Peripheral blood smear: Polychromatophilic RBCs, target cells, may show RBC morphology changes
• Iron studies: Iron deficiency common despite polycythemia (iron loss via hemolysis)
• Coagulation profile: Prolonged PT/INR and abnormal platelet function common
• Renal function and uric acid: Hyperuricemia predisposes to gout; renal dysfunction may develop
• Arterial blood gas: Hypoxemia with low PaO₂ (typically 50-75 mmHg), hypercapnia in advanced disease, normal to low HCO₃⁻ (metabolic acidosis may develop)
• B-type natriuretic peptide (BNP): Elevated, correlates with disease severity

• Computed Tomography (CT) Angiography:
• Confirms pulmonary artery dilatation and evaluates for pulmonary thromboemboli
• Assesses coronary anatomy if surgical intervention contemplated
• Rules out other causes of pulmonary hypertension

• Diagnostic Criteria for Eisenmenger Syndrome:
• Uncorrected congenital heart defect with left-to-right shunt
• Pulmonary vascular resistance elevated to suprasystemic levels (PVR typically >5-8 Wood units or >40 mmHg mean PA pressure)
• Bidirectional or predominantly right-to-left shunt confirmed by catheterization, echocardiography, or both
• Central cyanosis (SaO₂ typically 75-90%)
• Clinical, ECG, radiographic, and echocardiographic evidence of RV hypertrophy and dilation

• Pulmonary Vasodilatory Agents - First-Line Therapy:
• Phosphodiesterase-5 Inhibitors (PDE-5i): Sildenafil or tadalafil represent evidence-based first-line agents; act by increasing cGMP in vascular smooth muscle, promoting vasodilation and anti-proliferative effects; sildenafil dosing 40-60 mg daily in divided doses; tadalafil 40 mg daily; improve exercise capacity and symptoms; typically show modest hemodynamic improvement (PVR reduction 10-20%)
• Endothelin Receptor Antagonists (ERAs): Bosentan (125 mg BID) or ambrisentan (5-10 mg daily); block endothelin-1 mediated vasoconstriction and vascular remodeling; require baseline liver function assessment and monthly monitoring; efficacy comparable to PDE-5i; may be combined with other agents
• Soluble Guanylate Cyclase Stimulator: Riociguat (0.5-2.5 mg three times daily); promotes smooth muscle relaxation independent of nitric oxide availability; may be particularly beneficial in chronic thromboembolic complications

• Combination Therapy: Dual or triple agent therapy (PDE-5i + ERA + riociguat or inhaled prostanoid) increasingly employed in advanced cases; improves outcomes compared to monotherapy; requires careful titration and monitoring.

• Inhaled Pulmonary Vasodilators:
• Inhaled nitric oxide (iNO): 10-40 ppm; potent selective pulmonary vasodilator; useful acutely and for long-term therapy; requires specialized delivery systems; expensive
• Inhaled epoprostenol or iloprost: Prostacyclin analogs; promote vasodilation and reduce platelet aggregation; administered via nebulization; improve exercise capacity in some patients

• Anticoagulation:
• Warfarin or direct oral anticoagulants (DOACs) indicated for in-situ pulmonary thrombosis risk (relatively common in Eisenmenger); target INR 1.5-2.5 for warfarin; reduces sudden death and thromboembolism risk
• Antiplatelet agents (aspirin 81-325 mg daily) may provide additive benefit
• Balance thromboembolism risk against hemoptysis risk in advanced disease

• Phlebotomy and Iron Supplementation:
• Phlebotomy for symptomatic polycythemia (headache, visual disturbances, altered mental status) with hematocrit >65%; target hematocrit 50-55%; removes approximately 250-500 mL blood weekly
• Iron supplementation important despite polycythemia (iron deficiency from chronic hemolysis and phlebotomy impairs erythropoiesis and worsens anemia); oral ferrous sulfate 325 mg daily or IV iron if oral intolerance
• Avoid aggressive phlebotomy (depletes iron stores excessively)

• Oxygen Therapy:
• Supplemental oxygen for hypoxemia; improves oxygenation and reduces hypoxic pulmonary vasoconstriction; long-term home oxygen indicated for persistently low SaO₂ (<90%)
• Limited benefit in advanced disease but important for symptom relief

• Diuretics and Fluid Management:
• Loop diuretics (furosemide) for right heart failure with volume overload (peripheral edema, ascites, hepatomegaly)
• Sodium restriction (2-3 g daily)
• Judicious fluid management

Consequences of right-to-left shunting (loss of the pulmonary capillary filter)

• Paradoxical embolism and stroke: venous thrombi, air, or septic material bypass the lungs and enter the systemic circulation. Signaled by abrupt focal neurologic deficit — an emergency. All IV lines require air filters, a point the 2018 AHA/ACC Adult Congenital Heart Disease guideline emphasizes.
• Brain abscess: bacteremia escapes pulmonary filtration; suspect with headache, fever, seizure, or new focal deficit. Obtain contrast brain imaging urgently; emergency.
• Infective endocarditis: unrepaired cyanotic CHD is one of the few lesions for which the AHA still recommends dental antibiotic prophylaxis.

Hematologic and metabolic

• Hyperviscosity syndrome: headache, visual blurring, paresthesias, myalgia. Crucially, symptoms usually reflect iron-deficient microcytic erythrocytosis (rigid microcytes) or dehydration rather than the hematocrit itself.
• Bleeding diathesis: thrombocytopenia, acquired von Willebrand abnormality, and factor deficiencies coexist with thrombotic risk. Hemoptysis from dilated bronchial collaterals or in-situ pulmonary artery thrombosis may be massive — emergency.
• Hyperuricemia/gout, pigment gallstones (high RBC turnover), and proteinuric renal dysfunction from glomerular hyperfiltration and viscosity.

Cardiopulmonary

• Progressive RV failure: rising JVP, ascites, refractory edema, falling BNP-adjusted functional class.
• Atrial and ventricular arrhythmias and sudden cardiac death: fixed cardiac output makes tachyarrhythmia and syncope high-risk events warranting emergent evaluation.

Iatrogenic

• Overzealous phlebotomy: induces iron deficiency, which paradoxically worsens hyperviscosity and stroke risk.
• Any drug that lowers systemic vascular resistance (systemic vasodilators, spinal/epidural anesthesia, hot baths) increases right-to-left shunt and deepens cyanosis.
• Endothelin receptor antagonists: hepatotoxicity (bosentan), anemia, and teratogenicity with mandatory pregnancy prevention.
• Riociguat must not be given with a PDE-5 inhibitor — additive cGMP effect causes severe systemic hypotension.
• Dehydration, high altitude, and non-cardiac surgery are recognized precipitants of decompensation.
• Pregnancy carries markedly elevated maternal mortality (modified WHO class IV) and is discouraged per ACOG and AHA/ACC guidance.

• Closing the defect is contraindicated once Eisenmenger physiology is established: the shunt is the RV's "pop-off valve." Eliminating it converts suprasystemic pulmonary pressure into acute RV failure and death. This is the single most tested management point, and the 2018 AHA/ACC Adult Congenital Heart Disease guideline treats established Eisenmenger physiology as a contraindication to closure. Lung transplant with defect repair, or heart–lung transplant, is the only definitive therapy.
• Differential cyanosis and clubbing — pink fingers, blue and clubbed toes — is the buzzword for Eisenmenger from a PDA, because desaturated pulmonary arterial blood enters the aorta distal to the left subclavian. ASD/VSD-derived Eisenmenger produces uniform central cyanosis.
• The best next step in a symptomatic patient with a high hematocrit is iron studies and rehydration, not phlebotomy. Microcytosis from iron deficiency, not the hematocrit number, drives hyperviscosity symptoms; reflexive phlebotomy is the classic wrong answer.
• Never treat the erythrocytosis as polycythemia vera — it is an appropriate, EPO-driven compensatory response to hypoxemia, with a normal or elevated EPO level and no JAK2 mutation.
• Air filters on every IV line; any venous air or thrombus can embolize systemically. New focal neurologic deficit plus fever in a cyanotic adult should prompt imaging for brain abscess.
• Avoid anything that drops systemic vascular resistance (systemic vasodilators, neuraxial anesthesia, dehydration, high altitude) — the shunt reverses further and cyanosis deepens. Conversely, squatting raises SVR and improves saturation.
• Pregnancy is strongly discouraged (modified WHO class IV, ACOG); pulmonary vasodilators such as endothelin receptor antagonists are teratogenic, and estrogen contraception must be weighed against thrombotic risk.
• Vasoreactivity testing is essentially never positive in Eisenmenger — do not select calcium channel blockers, which can cause catastrophic systemic hypotension.